Patents by Inventor Carlos Martinez Fleites

Carlos Martinez Fleites has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Control Switch
    Publication number: 20220323494
    Abstract: The invention relates to a chimeric antigen receptor (CAR) suitable for the treatment of human subjects, comprising: (i) a signalling chain comprising a transmembrane domain and a signalling domain; (ii) a non-signalling chain comprising a target binding domain and a transmembrane domain; wherein, one of said chains further comprises a HIV Integrase catalytic core domain (CCD) or a functional fragment or variant thereof, and the other chain further comprises a LEDGF/p75 integrase binding domain (IBD), or a functional fragment or variant thereof.
    Type: Application
    Filed: October 14, 2019
    Publication date: October 13, 2022
    Inventors: Lewis Lee BRAYSHAW, Nicole CHRIST, Carlos MARTINEZ FLEITES
  • Targeted protein degradation
    Patent number: 11427643
    Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: August 30, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser
  • TARGETED PROTEIN DEGRADATION
    Publication number: 20200283538
    Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser
  • Targeted protein degradation
    Patent number: 10683360
    Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: June 16, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser
  • Targeted Protein Degradation
    Publication number: 20190002578
    Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.
    Type: Application
    Filed: July 2, 2018
    Publication date: January 3, 2019
    Inventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser